Bristol Myers Squibb was among the investors in a series B round announced alongside a collaboration with the small molecule drug developer.

US-based small molecule therapeutics developer Octant Bio has secured $80m in a series B round that included Bristol Myers Squibb (BMS), the pharmaceutical firm with which it recently struck a partnership.

Life sciences investment firm Catalio Capital Management led the round, which also featured boutique investment bank Allen & Company and venture capital firms 50 Years VC and Andreessen Horowitz, the latter through its Bio Fund.

Octant has developed a drug development technology platform which combines synthetic chemistry and computation…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.